ImmuCell swings to Q2 profit of $502k on 18% sales growth to $6.4M

IMMUCELL CORP /DE/

2025-Q2 EPS reported $0.22 revenue$14,512,054

Q2 product sales $6.4M, up 18% YoY; H1 sales $14.5M, up 14%.
Net income $502k ($0.06/diluted) vs loss of ($1.5M) in Q2 2024.
Gross margin improved to 44% from 22%; adjusted EBITDA $1.4M in Q2.
Cash rose to $6.0M from $3.8M at Dec 2024; no line-of-credit draws.
Re-Tain: initiating field feedback, reducing R&D spend, exploring strategic options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.